logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
C

Catherine J. Mummery

university college london
H指数:38
被引数:8,823

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Alzheimer's disease Stage 1 and 2: Biology, diagnostics, and treatment

阿尔茨海默病第1和第2阶段：生物学、诊断和治疗

alzheimer's & dementia: translational research & clinical interventions
IF0
2026-03-120
OAAI
Suzanne E. Schindler; Oskar Hansson; Alicia Algeciras-Schimnich; Jalayne J. Arias; Brent Beasley; Gill Farrar; Nicole R. Fowler; Sarah M. Hartz; Clifford R. Jack; Linus Jönsson; Geoffrey Joyce; Claire J. Lansdall; Paul Maruff; Niklas Mattsson-Carlgren; Catherine Jane Mummery; Jennifer Murphy; Hamid Okhravi; Ronald C. Petersen; Rema Raman; Christopher Randolph; Marie Reeberg Sass; Eric M. Reiman; Gemma Salvadó; Michael Schöll; Eric Siemers; Reisa A. Sperling; Tricia Thornton-Wells; Rosanna Tortelli; Duygu Tosun; Lawren Vandevrede; Nicolas Villain; Stacie Weninger; Alette M. Wessels; Jin Zhou; Maria C. Carrillo; Christopher J. Weber
The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial

TREM2激动性抗体AL002在早期阿尔茨海默病中的应用: 一项2期随机试验

Nature Medicine
IF50
2026-03-050
PRE
Catherine J. Mummery; Arthur J. Mayorga; Adam Simmons; Tiffany W. Chow; Brady Burgess; Tuan Nguyen; Jingjing Gao; Balasubrahmanyam Budda; Lovingly Quitania Park; Ruchi Gupta; Caiyan Li; Li Shi; Sara Kenkare-Mitra; Arnon Rosenthal; Robert Paul; Michael Ward; Derk D. Purcell; Stephen Salloway; Michael Grundman; Gary Romano; Giacomo Salvadore
Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies

治疗相关淀粉样蛋白清除（TRAC）：一种在抗淀粉样蛋白疗法时代用于表征患者的框架

ALZHEIMERS & DEMENTIA
IF11.1
2025-11-260
OAAI
La Joie, Renaud; Cummings, Jeffrey L.; Dage, Jeffrey L.; Galasko, Douglas; Ikonomovic, Milos D.; Karikari, Thomas K.; Landau, Susan M.; Llibre-guerra, Jorge J.; Mummery, Catherine J.; Ossenkoppele, Rik; Price, Julie C.; Risacher, Shannon L.; Smith, Ruben; van Dyck, Christopher H.; Carrillo, Maria C.
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

可溶性tau物种与阿尔茨海默病淀粉样斑块清除及tau病理的关系

Alzheimer's & Dementia
IF11.1
2025-09-230
OAAI
Eric M. McDade; Nicolas R. Barthélemy; Guoqiao Wang; Yan Li; Yuchen Cao; Brian Gordon; Tammie L. S. Benzinger; David Clifford; Alison M. Goate; Alan E. Renton; Jason Hassenstab; Jorge J. Llibre-Guerra; Richard J. Perrin; Chengjie Xiong; Carlos Cruchaga; Catherine J. Mummery; Sarah B. Berman; James Lah; Erik D. Roberson; Christopher Van Dyck; Serge Gauthier; Colin L. Masters; Mario Masellis; Tobias Bittner; Roy Yaari; Jasmeer Chhatwal; Patricio Chrem; William Brooks; Kazushi Suzuki; Johannes J. Levin; Mathias Jucker; John Ringman; David Wallon; Takeshi Ikeuchi; Jae-Hong Lee; Jee Hoon Roh; Peter Schofield; Nick C. Fox; Natalie S. Ryan; Jonathan Vöglein; Celeste Karch; Laura Ibáñez; Gregory S. Day; Raquel Sánchez-Valle; Alisha Daniels; John C. Morris; Charlene Supnet-Bell; Allan I. Levey; Randall J. Bateman; The DIAN-TU Study Team and DIAN Obs Team
Treatment for Alzheimer's disease

阿尔茨海默病治疗

The Lancet
IF0
2025-09-220
OAAI
Nick C Fox; Christopher Belder; Clive Ballard; Helen C Kales; Catherine Mummery; Paulo Caramelli; Olga Ciccarelli; Kristian S Frederiksen; Teresa Gomez-Isla; Zahinoor Ismail; Claire Paquet; Ronald C Petersen; Robert Perneczky; Louise Robinson; Ozge Sayin; Giovanni B Frisoni
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study

两种靶向Tau蛋白的主动免疫疗法（ACI-35.030和JACI-35.054）在早期阿尔茨海默病受试者中的安全性与免疫原性：一项1b/2a期、多中心、双盲、随机、安慰剂对照研究

eBioMedicine
IF10.8
2025-09-180
PREAI
Olivier Sol; Julien Mermoud; Merja Hallikainen; Sudhir Kurl; Juha Rinne; Paul Dautzenberg; Everard G.B. Vijverberg; Catherine Mummery; Anne Börjesson-Hanson; Michael Jonsson; Craig Ritchie; Catherine Pennington; Marija Vukicevic; Eva Gollwitzer; Emma Fiorini; David T. Hickman; Valérie Hliva; Julian Gray; Viktoriia Gerasymchuk; Jonathan Wagg; Nicolas Fournier; Bénédicte Lê; Iva Kezic; Lennert Steukers; Gallen Triana-Baltzer; Clara Theunis; Johannes Streffer; Marie Kosco-Vilbois; Andrea Pfeifer; Philip Scheltens
Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease

抗淀粉样蛋白治疗的资格: 为阿尔茨海默病的疾病改善疗法做准备

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
IF7.5
2024-06-112
OAAI
Dobson, Ruth; Patterson, Katherine; Malik, Reshad; Mandal, Uttara; Asif, Hina; Humphreys, Ros; Payne, Michael; O-Charoenrat, Eng; Huzzey, Lauren; Clare, Adam; Green, Kate; Morton, Maija; Sohrabi, Catrin; Singh, Navreen; Pasupathy, Amirtha; Patel, Milan; Whiteman, Sam; Maxmin, Kate; Bass, Nicholas; Gupta, Bhavya; Cooper, Claudia; Marshall, Charles; Weil, Rimona Sharon; Mummery, Catherine J.
Decentralized clinical trials for medications to reduce the risk of dementia: Consensus report and guidance

降低痴呆症风险的药物分散临床试验: 共识报告和指南

ALZHEIMERS & DEMENTIA
IF11.1
2024-06-020
OA
Howard, Leanne; Abdelnour, Carla; Abner, Erin L.; Allegri, Ricardo F.; Dodge, Hiroko H.; Gauthier, Serge; Hoyos, Camilla M.; Jicha, Gregory A.; Kehoe, Patrick G.; Mummery, Catherine J.; Ogunniyi, Adesola; Scarmeas, Nikolaos; Chen, Xiaoying; Titiner, Jodie R.; Weber, Christopher R.; Peters, Ruth
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
IF7.8
2024-05-011
PRE
Liu, Haiyan; Li, J.; Ziegemeier, E.; Adams, S.; Mcdade, E.; Clifford, D. B.; Cao, Y.; Wang, G.; Li, Y.; Mills, S. L.; Santacruz, A. M.; Belyew, S.; Grill, J. D.; Snider, B. J.; Mummery, C. J.; Surti, G.; Hannequin, D.; Wallon, D.; Berman, S. B.; Jimenez-Velazquez, I. Z.; Roberson, E. D.; van Dyck, C. H.; Honig, L. S.; Sanchez-Valle, R.; Brooks, W. S.; Gauthier, S.; Galasko, D.; Masters, C. L.; Brosch, J.; Hsiung, G. -Y. R.; Jayadev, S.; Formaglio, M.; Masellis, M.; Clarnette, R.; Pariente, J.; Dubois, B.; Pasquier, F.; Bateman, R. J.; Llibre-Guerra, Jorge J.
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
ALZHEIMERS & DEMENTIA
IF11.1
2024-02-231
OAAI
Wang, Guoqiao; Li, Yan; Xiong, Chengjie; Benzinger, Tammie L. S.; Gordon, Brian A.; Hassenstab, Jason; Aschenbrenner, Andrew J.; McDade, Eric; Clifford, David B.; Libre-Guerra, Jorge J.; Shi, Xinyu; Mummery, Catherine J.; van Dyck, Christopher H.; Lah, James J.; Honig, Lawrence S.; Day, Gregg; Ringman, John M.; Brooks, William S.; Fox, Nick C.; Suzuki, Kazushi; Levin, Johannes; Jucker, Mathias; Delmar, Paul; Bittner, Tobias; Bateman, Randall J.
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial (vol 29, pg 1437, 2023)
NATURE MEDICINE
IF50
2023-10-160
OAAI
Mummery, Catherine J.; Borjesson-Hanson, Anne; Blackburn, Daniel J.; Vijverberg, Everard G. B.; De Deyn, Peter Paul; Ducharme, Simon; Jonsson, Michael; Schneider, Anja; Rinne, Juha O.; Ludolph, Albert C.; Bodenschatz, Ralf; Kordasiewicz, Holly; Swayze, Eric E.; Fitzsimmons, Bethany; Mignon, Laurence; Moore, Katrina M.; Yun, Chris; Baumann, Tiffany; Li, Dan; Norris, Daniel A.; Crean, Rebecca; Graham, Danielle L.; Huang, Ellen; Ratti, Elena; Bennett, C. Frank; Junge, Candice; Lane, Roger M.
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

Tau靶向反义寡核苷酸MAPTRx治疗轻度阿尔茨海默病: 1b期，随机，安慰剂对照试验

NATURE MEDICINE
IF50
2023-04-24109
OAAI
Mummery, Catherine J.; Borjesson-Hanson, Anne; Blackburn, Daniel J.; Vijverberg, Everard G. B.; De Deyn, Peter Paul; Ducharme, Simon; Jonsson, Michael; Schneider, Anja; Rinne, Juha O.; Ludolph, Albert C.; Bodenschatz, Ralf; Kordasiewicz, Holly; Swayze, Eric E.; Fitzsimmons, Bethany; Mignon, Laurence; Moore, Katrina M.; Yun, Chris; Baumann, Tiffany; Li, Dan; Norris, Daniel A.; Crean, Rebecca; Graham, Danielle L.; Huang, Ellen; Ratti, Elena; Bennett, C. Frank; Junge, Candice; Lane, Roger M.
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
IF4.4
2022-11-036
OA
Wang, Guoqiao; Li, Yan; Xiong, Chengjie; McDade, Eric; Clifford, David B.; Mills, Susan L.; Santacruz, Anna M.; Aschenbrenner, Andrew J.; Hassenstab, Jason; Benzinger, Tammie L. S.; Gordon, Brian A.; Fagan, Anne M.; Coalier, Kelley A.; Libre-Guerra, Jorge J.; McCullough, Austin; Joseph-Mathurin, Nelly; Chen, Charles D.; Mummery, Catherine; Wendelberger, Barbara A.; Gauthier, Serge; Masellis, Mario; Holdridge, Karen C.; Yaari, Roy; Chatterjee, Saptarshi; Sims, John; Delmar, Paul; Kerchner, Geoffrey A.; Bittner, Tobias; Hofmann, Carsten; Bateman, Randall J.

研究方向

暂未获取到该数据
J
Jason D. Warren
H 指数:96论文数:773被引数:4.2万
J
Jonathan M. Schott
H 指数:90论文数:722被引数:4.1万
N
Nick C. Fox
H 指数:173论文数:1,531被引数:17.2万
H
Hannah L. Golden
H 指数:25论文数:48被引数:2,133
J
Jonathan D. Rohrer
H 指数:89论文数:696被引数:3.9万
S
Sebastian J. Crutch
H 指数:59论文数:525被引数:1.8万
J
Jennifer M. Nicholas
H 指数:38论文数:210被引数:5,792
C
Camilla N. Clark
H 指数:24论文数:88被引数:2,274
L
Laura Downey
H 指数:30论文数:127被引数:3,034
R
Randall J. Bateman
H 指数:95论文数:809被引数:5.2万